

t 1300 788 261 f 1300 788 262 w medsurge.com.au

Unit 1&2, 6-7 Gilda Court Mulgrave, VIC 3170, Australia

ABN 92 124 728 892

20 June 2023

Dear Healthcare Professional

Shortage of PERSANTIN dipyridamole 10mg/2mL injection ampoule and alternate supply arrangement under Section 19A of the *Therapeutic Goods Act*.

The Australian registered medicine PERSANTIN dipyridamole 10mg/2mL injection ampoule (AUST R 17934) sponsored by Clinect Pty Ltd is in shortage due to manufacturing issues.

Medsurge has been able to arrange for the supply of **POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan)** as an alternative product on a temporary basis. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the *Therapeutic Goods Act 1989* until **30 April 2024** for the following indication:

- indicated as an alternative to exercise in myocardial imaging.

POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan) is registered and marketed in Taiwan by Nangkuang Pharmaceutical Co., Ltd and therefore all labelling is in Chinese. The active ingredient, strength and pack size are identifiable in English. An English translation of the Summary of Product Characteristics will be supplied with the product. Medsurge recommends that healthcare professionals refer to the Australian Product Information (PI) for recommended dosing for the above indication, available from https://www.ebs.tga.gov.au/.

A comparison table of differences between Australian registered product PERSANTIN dipyridamole 10mg/2mL injection ampoule (AUST R 17934) and the Taiwanese product POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan) is given below:

	PERSANTIN dipyridamole 10mg/2mL injection ampoule (AUST R 17934)	POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan) (S19A product)
Excipients	tartaric acid, macrogol 600 (<i>polyethylene glycol 600</i>), hydrochloric acid (to adjust pH) water for injections.	tartaric acid, polyethylene glycol 400, hydrochloric acid water for injection.
Pack size	Boxes of 5 ampoules.	Boxes of 50 ampoules.

Reporting any suspected adverse event is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan)** should be reported by healthcare professionals, pharmacists, and patients to

Medsurge on 1300 788 261 or email <u>sales@medsurge.com.au.</u> Alternatively, this information can be reported to the TGA at https://www.tga.gov.au/reporting-problems.

Any product complaints with **POSINTIN INJ. N.K dipyridamole 10mg/2mL injection ampoule (Taiwan)** should be reported to Medsurge on 1300 788 261 or email sales@medsurge.com.au.

Please forward this information to relevant staff members in your organisation.

For further information, please contact Medsurge Healthcare on 1300 788 261 or email sales@medsurge.com.au

Yours Sincerely,

Scientific Affairs Associate Medsurge Healthcare